# AB-205

Source: https://onco.cc/drugs/ab-205/  
OnCo record `ab-205` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AB-205 is an experimental allogeneic engineered endothelial cell therapy from Angiocrine Bioscience, in phase 3 trials for hodgkin lymphoma and non-Hodgkin lymphoma; its current status is not stated.

## Summary

AB-205 (E-CEL cells) is an allogeneic engineered endothelial cell therapy (genetically engineered human umbilical vein endothelial cells) from Angiocrine Bioscience, with California Institute for Regenerative Medicine as partner. Infused engineered blood-vessel lining cells meant to prevent or reduce the severe organ complications of high-dose chemotherapy before an autologous stem cell transplant. Supportive care for people with lymphoma, not a treatment of the cancer itself. Its furthest stage is phase 3, for hodgkin lymphoma and non-Hodgkin lymphoma (patients undergoing high-dose therapy and autologous transplant). ClinicalTrials.gov registers it in 2 studies linked below. Phase 3 E-CELERATE NCT05181540 TERMINATED: registry reason 'Interim analysis showed lack of efficacy'. No company statement on the programme found. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-11-03
- Also known as: E-CEL cells
- Tags: pipeline; ctgov-ingest
- Code: AB-205
- Modality: Allogeneic engineered endothelial cell therapy (genetically engineered human umbilical vein endothelial cells)
- Mechanism: Infused engineered blood-vessel lining cells meant to prevent or reduce the severe organ complications of high-dose chemotherapy before an autologous stem cell transplant. Supportive care for people with lymphoma, not a treatment of the cancer itself.

## Sources

- Angiocrine Bioscience: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05181540
- Angiocrine Bioscience: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05181540
- Angiocrine Bioscience: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05181540
- ClinicalTrials.gov: trials of AB-205: https://clinicaltrials.gov/search?intr=AB-205

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/)
- trials: [A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation](https://onco.cc/trials/nct05181540/), [Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation](https://onco.cc/trials/nct03925935/)

---
JSON: https://onco.cc/api/v1/entities/ab-205.json